2026 Hemostasis Gordon Research Conference and Seminar

About This Grant

Project Summary – 2026 Hemostasis GRS and GRC We request partial support for the 2026 Hemostasis Gordon Research Seminar (GRS) and Gordon Research Conference (GRC), to be held August 1–7, 2026, in Waterville Valley, New Hampshire. The 2026 meeting, titled “Integrative Mechanisms of Hemostasis in Health and Disease,” will be the 37th in this highly regarded series and continues its tradition as the premier forum for the presentation and discussion of cutting-edge research in hemostasis and thrombosis. This meeting directly supports two core NIH strategic priorities: (1) advancing the mechanistic understanding and clinical translation of therapies for thrombotic and bleeding disorders—including stroke, myocardial infarction, venous thromboembolism, and trauma-induced coagulopathy—and (2) cultivating a robust and knowledgeable biomedical research workforce. It also reflects the growing recognition that the hemostatic system plays critical roles beyond clot formation, including in inflammation, innate and adaptive immunity, cancer, obesity, and metabolic disease. The GRS and GRC bring together a multidisciplinary group of scientists: basic researchers focused on the biochemistry, cell biology, and genetics of platelets and coagulation factors; clinician-scientists treating bleeding and thrombotic diseases; pharmaceutical and biotechnology investigators developing new therapies; and a vibrant group of trainees and junior faculty. These participants engage in the open exchange of unpublished findings, engage in critical discussion, and foster collaborations that often lead to transformative discoveries. Many key advances in the field of hemostasis and thrombosis have debuted at past Hemostasis GRCs. A key strength of the GRS/GRC is its commitment to early-career development. The GRS, organized by trainees for trainees, offers a platform for graduate students and postdoctoral fellows to present their work, gain feedback, and interact with senior scientists in a focused, mentoring-rich environment. The GRS also features a keynote lecture and professional development session to support the transition into independent research careers. Participation in the GRC further integrates these early-career investigators into the broader scientific community. The 2026 program will feature keynote lectures from two leading physician-scientists—Dr. Barry Coller, who studies molecular therapies for thrombotic diseases, and Dr. Mitchell Kornblith, a trauma surgeon applying multiomic approaches to platelet dysfunction in traumatic brain injury. The GRC will include 39 invited talks and eight scientific sessions spanning mechanistic and translational topics, including: endothelial resistance to thrombosis, platelet proteomics, thromboinflammatory signaling, vascular-immune crosstalk, and systems-level regulation of hemostasis. In addition, four poster sessions and the highly successful “Hot Topics” session will spotlight short talks from eight top-ranked trainee abstracts. Through its integrative scientific focus, commitment to mentorship, and active engagement across academic and sectors, the 2026 Hemostasis GRS and GRC will continue to advance the mission of the NHLBI playing a pivotal role in shaping the future of blood science.